+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Intravenous: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 220 Pages
  • July 2024
  • Region: Global
  • Allied Market Research
  • ID: 5994318
The intravenous (IV) hydration therapy market was valued at $2.3 billion in 2023 and is projected to reach $4.9 billion by 2033, growing at a CAGR of 7.8% from 2024 to 2033.

Intravenous (IV) hydration therapy is the medical procedure in which medications, fluids, vitamins, and electrolytes are infused directly into the bloodstream through a vein. The therapy is a highly effective procedure as it ensures efficient and quick replenishment of essential fluids and nutrients lost due to dehydration. Dehydration is the excessive loss of fluids from the body caused by some illness, excessive alcohol consumption, or intense physical activity. The treatment is applicable in diverse medical settings for the management of chronic conditions, preoperative & postoperative care, and to cure patients with severe infections or gastrointestinal problems.

One of the key drivers of the intravenous (IV) hydration therapy market is increase in uptight lifestyle among individuals with high stress levels. A stressed lifestyle is one of the most common reasons for rising dehydration among individuals. In addition, the geriatric population is growing exponentially across the globe, who are highly susceptible to ailments and hospitalization. This boosts the demand for IV hydration therapy, thus augmenting the market growth. In recent times, the administration of IV therapy as a part of self-care routine or rejuvenation is trending, particularly among celebrities. Moreover, specialized centers called “hydration bars” are being established for people to receive therapy as a form of relaxation.

However, the availability of other alternatives for hydration therapy, such as the oral rehydration solutions restrain the development of the market. Furthermore, the shortage of dedicated medical facilities and well-trained staff, particularly in rural areas, presents challenges for the expansion of the market. On the contrary, advancements in technology and modifications in the conventional formulations administered during treatment are presenting lucrative opportunities for market growth. For instance, personalized solutions are being developed according to the requirements of every individual, hence aiding them to achieve their health goal.

Segment Review

The intravenous (IV) hydration therapy market is segmented into service, component, end user, and region. On the basis of service, the market is divided into immune boosters, energy boosters, skin care, migraine, and others. By component, it is bifurcated into medicated and non-medicated. As per end user, it is categorized into hospital & clinics, wellness centers & spas, home healthcare, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of service, the immune boosters segment dominates the market.

By component, the medicated segmented experiences significant demand in the market.

As per end user, the hospital & clinics segment acquires a high share of the market.

Region wise, North America leads the market.

Competition Analysis

The major players operating in the global intravenous (IV) hydration therapy market include Davita, Nikkiso Co. Ltd., Core IV Therapy, LLC, Cryojuvenate UK Ltd., B. Braun Medical Inc., Otsuka Pharmaceutical Co., Ltd., NexGen Health, JW Life Science Corporation, Amanta Healthcare Limited., and Baxter International Inc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data
  • Reimbursement Scenario

Key Market Segments

By Service

  • Immune boosters
  • Energy boosters
  • Skin care
  • Migraine
  • Others

By Component

  • Medicated
  • Non-medicated

By End User

  • Hospital clinics
  • Wellness centers spas
  • Home healthcare
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
Key Market Players
  • Davita
  • Nikkiso Co. Ltd.
  • Core IV Therapy, LLC
  • Cryojuvenate UK Ltd.
  • B. Braun Medical Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • NexGen Health
  • JW Life Science Corporation
  • Amanta Healthcare Limited.
  • Baxter International Inc.?

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY SERVICE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Service
4.2. Immune Boosters
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Energy Boosters
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Skin Care
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Migraine
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY COMPONENT
5.1. Market Overview
5.1.1 Market Size and Forecast, By Component
5.2. Medicated
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Non-medicated
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Hospital Clinics
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Wellness Centers Spas
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Home Healthcare
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Others
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: INTRAVENOUS (IV) HYDRATION THERAPY MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Service
7.2.3. Market Size and Forecast, By Component
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Intravenous (IV) Hydration Therapy Market
7.2.6.1. Market Size and Forecast, By Service
7.2.6.2. Market Size and Forecast, By Component
7.2.6.3. Market Size and Forecast, By End User
7.2.7. Canada Intravenous (IV) Hydration Therapy Market
7.2.7.1. Market Size and Forecast, By Service
7.2.7.2. Market Size and Forecast, By Component
7.2.7.3. Market Size and Forecast, By End User
7.2.8. Mexico Intravenous (IV) Hydration Therapy Market
7.2.8.1. Market Size and Forecast, By Service
7.2.8.2. Market Size and Forecast, By Component
7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Service
7.3.3. Market Size and Forecast, By Component
7.3.4. Market Size and Forecast, By End User
7.3.5. Market Size and Forecast, By Country
7.3.6. France Intravenous (IV) Hydration Therapy Market
7.3.6.1. Market Size and Forecast, By Service
7.3.6.2. Market Size and Forecast, By Component
7.3.6.3. Market Size and Forecast, By End User
7.3.7. Germany Intravenous (IV) Hydration Therapy Market
7.3.7.1. Market Size and Forecast, By Service
7.3.7.2. Market Size and Forecast, By Component
7.3.7.3. Market Size and Forecast, By End User
7.3.8. Italy Intravenous (IV) Hydration Therapy Market
7.3.8.1. Market Size and Forecast, By Service
7.3.8.2. Market Size and Forecast, By Component
7.3.8.3. Market Size and Forecast, By End User
7.3.9. Spain Intravenous (IV) Hydration Therapy Market
7.3.9.1. Market Size and Forecast, By Service
7.3.9.2. Market Size and Forecast, By Component
7.3.9.3. Market Size and Forecast, By End User
7.3.10. UK Intravenous (IV) Hydration Therapy Market
7.3.10.1. Market Size and Forecast, By Service
7.3.10.2. Market Size and Forecast, By Component
7.3.10.3. Market Size and Forecast, By End User
7.3.11. Rest of Europe Intravenous (IV) Hydration Therapy Market
7.3.11.1. Market Size and Forecast, By Service
7.3.11.2. Market Size and Forecast, By Component
7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Service
7.4.3. Market Size and Forecast, By Component
7.4.4. Market Size and Forecast, By End User
7.4.5. Market Size and Forecast, By Country
7.4.6. China Intravenous (IV) Hydration Therapy Market
7.4.6.1. Market Size and Forecast, By Service
7.4.6.2. Market Size and Forecast, By Component
7.4.6.3. Market Size and Forecast, By End User
7.4.7. Japan Intravenous (IV) Hydration Therapy Market
7.4.7.1. Market Size and Forecast, By Service
7.4.7.2. Market Size and Forecast, By Component
7.4.7.3. Market Size and Forecast, By End User
7.4.8. India Intravenous (IV) Hydration Therapy Market
7.4.8.1. Market Size and Forecast, By Service
7.4.8.2. Market Size and Forecast, By Component
7.4.8.3. Market Size and Forecast, By End User
7.4.9. South Korea Intravenous (IV) Hydration Therapy Market
7.4.9.1. Market Size and Forecast, By Service
7.4.9.2. Market Size and Forecast, By Component
7.4.9.3. Market Size and Forecast, By End User
7.4.10. Australia Intravenous (IV) Hydration Therapy Market
7.4.10.1. Market Size and Forecast, By Service
7.4.10.2. Market Size and Forecast, By Component
7.4.10.3. Market Size and Forecast, By End User
7.4.11. Rest of Asia-Pacific Intravenous (IV) Hydration Therapy Market
7.4.11.1. Market Size and Forecast, By Service
7.4.11.2. Market Size and Forecast, By Component
7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Service
7.5.3. Market Size and Forecast, By Component
7.5.4. Market Size and Forecast, By End User
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Intravenous (IV) Hydration Therapy Market
7.5.6.1. Market Size and Forecast, By Service
7.5.6.2. Market Size and Forecast, By Component
7.5.6.3. Market Size and Forecast, By End User
7.5.7. South Africa Intravenous (IV) Hydration Therapy Market
7.5.7.1. Market Size and Forecast, By Service
7.5.7.2. Market Size and Forecast, By Component
7.5.7.3. Market Size and Forecast, By End User
7.5.8. Saudi Arabia Intravenous (IV) Hydration Therapy Market
7.5.8.1. Market Size and Forecast, By Service
7.5.8.2. Market Size and Forecast, By Component
7.5.8.3. Market Size and Forecast, By End User
7.5.9. Rest of LAMEA Intravenous (IV) Hydration Therapy Market
7.5.9.1. Market Size and Forecast, By Service
7.5.9.2. Market Size and Forecast, By Component
7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Davita
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Nikkiso Co. Ltd.
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Core IV Therapy, LLC
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Cryojuvenate UK Ltd.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. B. Braun Medical Inc.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Otsuka Pharmaceutical Co., Ltd.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. NexGen Health
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. JW Life Science Corporation
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Amanta Healthcare Limited.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Baxter International Inc.?
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
Table 1. Global Intravenous (IV) Hydration Therapy Market, by Service, 2024 - 2033 ($Billion)
Table 2. Intravenous (IV) Hydration Therapy Market for Immune Boosters, by Region, 2024 - 2033 ($Billion)
Table 3. Intravenous (IV) Hydration Therapy Market for Energy Boosters, by Region, 2024 - 2033 ($Billion)
Table 4. Intravenous (IV) Hydration Therapy Market for Skin Care, by Region, 2024 - 2033 ($Billion)
Table 5. Intravenous (IV) Hydration Therapy Market for Migraine, by Region, 2024 - 2033 ($Billion)
Table 6. Intravenous (IV) Hydration Therapy Market for Others, by Region, 2024 - 2033 ($Billion)
Table 7. Global Intravenous (IV) Hydration Therapy Market, by Component, 2024 - 2033 ($Billion)
Table 8. Intravenous (IV) Hydration Therapy Market for Medicated, by Region, 2024 - 2033 ($Billion)
Table 9. Intravenous (IV) Hydration Therapy Market for Non-Medicated, by Region, 2024 - 2033 ($Billion)
Table 10. Global Intravenous (IV) Hydration Therapy Market, by End-user, 2024 - 2033 ($Billion)
Table 11. Intravenous (IV) Hydration Therapy Market for Hospital Clinics, by Region, 2024 - 2033 ($Billion)
Table 12. Intravenous (IV) Hydration Therapy Market for Wellness Centers Spas, by Region, 2024 - 2033 ($Billion)
Table 13. Intravenous (IV) Hydration Therapy Market for Home Healthcare, by Region, 2024 - 2033 ($Billion)
Table 14. Intravenous (IV) Hydration Therapy Market for Others, by Region, 2024 - 2033 ($Billion)
Table 15. Intravenous (IV) Hydration Therapy Market, by Region, 2024 - 2033 ($Billion)
Table 16. North America Intravenous (IV) Hydration Therapy, by Country, 2024 - 2033 ($Billion)
Table 17. North America Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 18. North America Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 19. North America Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 20. U.S. Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 21. U.S. Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 22. U.S. Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 23. Canada Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 24. Canada Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 25. Canada Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 26. Mexico Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 27. Mexico Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 28. Mexico Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 29. Europe Intravenous (IV) Hydration Therapy, by Country, 2024 - 2033 ($Billion)
Table 30. Europe Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 31. Europe Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 32. Europe Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 33. France Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 34. France Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 35. France Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 36. Germany Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 37. Germany Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 38. Germany Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 39. Italy Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 40. Italy Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 41. Italy Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 42. Spain Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 43. Spain Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 44. Spain Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 45. UK Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 46. UK Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 47. UK Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 48. Rest of Europe Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 49. Rest of Europe Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 50. Rest of Europe Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 51. Asia-Pacific Intravenous (IV) Hydration Therapy, by Country, 2024 - 2033 ($Billion)
Table 52. Asia-Pacific Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 53. Asia-Pacific Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 54. Asia-Pacific Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 55. China Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 56. China Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 57. China Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 58. Japan Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 59. Japan Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 60. Japan Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 61. India Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 62. India Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 63. India Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 64. South Korea Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 65. South Korea Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 66. South Korea Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 67. Australia Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 68. Australia Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 69. Australia Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 70. Rest of Asia-Pacific Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 71. Rest of Asia-Pacific Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 72. Rest of Asia-Pacific Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 73. LAMEA Intravenous (IV) Hydration Therapy, by Country, 2024 - 2033 ($Billion)
Table 74. LAMEA Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 75. LAMEA Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 76. LAMEA Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 77. Brazil Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 78. Brazil Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 79. Brazil Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 80. South Africa Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 81. South Africa Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 82. South Africa Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 83. Saudi Arabia Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 84. Saudi Arabia Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 85. Saudi Arabia Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 86. Rest of LAMEA Intravenous (IV) Hydration Therapy, by Service, 2024 - 2033 ($Billion)
Table 87. Rest of LAMEA Intravenous (IV) Hydration Therapy, by Component, 2024 - 2033 ($Billion)
Table 88. Rest of LAMEA Intravenous (IV) Hydration Therapy, by End-user, 2024 - 2033 ($Billion)
Table 89. Davita: Key Executives
Table 90. Davita: Company Snapshot
Table 91. Davita: Operating Segments
Table 92. Davita: Product Portfolio
Table 93. Davita: Key Strategic Moves and Developments
Table 94. Nikkiso Co. Ltd.: Key Executives
Table 95. Nikkiso Co. Ltd.: Company Snapshot
Table 96. Nikkiso Co. Ltd.: Operating Segments
Table 97. Nikkiso Co. Ltd.: Product Portfolio
Table 98. Nikkiso Co. Ltd.: Key Strategic Moves and Developments
Table 99. Core IV Therapy, LLC: Key Executives
Table 100. Core IV Therapy, LLC: Company Snapshot
Table 101. Core IV Therapy, LLC: Operating Segments
Table 102. Core IV Therapy, LLC: Product Portfolio
Table 103. Core IV Therapy, LLC: Key Strategic Moves and Developments
Table 104. Cryojuvenate UK Ltd.: Key Executives
Table 105. Cryojuvenate UK Ltd.: Company Snapshot
Table 106. Cryojuvenate UK Ltd.: Operating Segments
Table 107. Cryojuvenate UK Ltd.: Product Portfolio
Table 108. Cryojuvenate UK Ltd.: Key Strategic Moves and Developments
Table 109. B. Braun Medical Inc.: Key Executives
Table 110. B. Braun Medical Inc.: Company Snapshot
Table 111. B. Braun Medical Inc.: Operating Segments
Table 112. B. Braun Medical Inc.: Product Portfolio
Table 113. B. Braun Medical Inc.: Key Strategic Moves and Developments
Table 114. Otsuka Pharmaceutical Co. Ltd.: Key Executives
Table 115. Otsuka Pharmaceutical Co. Ltd.: Company Snapshot
Table 116. Otsuka Pharmaceutical Co. Ltd.: Operating Segments
Table 117. Otsuka Pharmaceutical Co. Ltd.: Product Portfolio
Table 118. Otsuka Pharmaceutical Co. Ltd.: Key Strategic Moves and Developments
Table 119. Nexgen Health: Key Executives
Table 120. Nexgen Health: Company Snapshot
Table 121. Nexgen Health: Operating Segments
Table 122. Nexgen Health: Product Portfolio
Table 123. Nexgen Health: Key Strategic Moves and Developments
Table 124. Jw Life Science Corporation: Key Executives
Table 125. Jw Life Science Corporation: Company Snapshot
Table 126. Jw Life Science Corporation: Operating Segments
Table 127. Jw Life Science Corporation: Product Portfolio
Table 128. Jw Life Science Corporation: Key Strategic Moves and Developments
Table 129. Amanta Healthcare Limited.: Key Executives
Table 130. Amanta Healthcare Limited.: Company Snapshot
Table 131. Amanta Healthcare Limited.: Operating Segments
Table 132. Amanta Healthcare Limited.: Product Portfolio
Table 133. Amanta Healthcare Limited.: Key Strategic Moves and Developments
Table 134. Baxter International Inc.?: Key Executives
Table 135. Baxter International Inc.?: Company Snapshot
Table 136. Baxter International Inc.?: Operating Segments
Table 137. Baxter International Inc.?: Product Portfolio
Table 138. Baxter International Inc.?: Key Strategic Moves and Developments
LIST OF FIGURES
Figure 1. Global Intravenous (IV) Hydration Therapy Market Segmentation
Figure 2. Global Intravenous (IV) Hydration Therapy Market
Figure 3. Segmentation Intravenous (IV) Hydration Therapy Market
Figure 4. Top Investment Pocket in Intravenous (IV) Hydration Therapy Market
Figure 5. Moderate Bargaining Power of Buyers
Figure 6. Moderate Bargaining Power of Suppliers
Figure 7. Moderate Threat of New Entrants
Figure 8. Low Threat of Substitution
Figure 9. High Competitive Rivalry
Figure 10. Opportunities, Restraints and Drivers: Globalintravenous (IV) Hydration Therapy Market
Figure 11. Global Intravenous (IV) Hydration Therapy Market Segmentation, by Service
Figure 12. Intravenous (IV) Hydration Therapy Market for Immune Boosters, by Country, 2024 - 2033 ($Billion)
Figure 13. Intravenous (IV) Hydration Therapy Market for Energy Boosters, by Country, 2024 - 2033 ($Billion)
Figure 14. Intravenous (IV) Hydration Therapy Market for Skin Care, by Country, 2024 - 2033 ($Billion)
Figure 15. Intravenous (IV) Hydration Therapy Market for Migraine, by Country, 2024 - 2033 ($Billion)
Figure 16. Intravenous (IV) Hydration Therapy Market for Others, by Country, 2024 - 2033 ($Billion)
Figure 17. Global Intravenous (IV) Hydration Therapy Market Segmentation, by Component
Figure 18. Intravenous (IV) Hydration Therapy Market for Medicated, by Country, 2024 - 2033 ($Billion)
Figure 19. Intravenous (IV) Hydration Therapy Market for Non-Medicated, by Country, 2024 - 2033 ($Billion)
Figure 20. Global Intravenous (IV) Hydration Therapy Market Segmentation, by End-user
Figure 21. Intravenous (IV) Hydration Therapy Market for Hospital Clinics, by Country, 2024 - 2033 ($Billion)
Figure 22. Intravenous (IV) Hydration Therapy Market for Wellness Centers Spas, by Country, 2024 - 2033 ($Billion)
Figure 23. Intravenous (IV) Hydration Therapy Market for Home Healthcare, by Country, 2024 - 2033 ($Billion)
Figure 24. Intravenous (IV) Hydration Therapy Market for Others, by Country, 2024 - 2033 ($Billion)
Figure 25. Top Winning Strategies, by Year, 2021-2023*
Figure 26. Top Winning Strategies, by Development, 2021-2023*
Figure 27. Top Winning Strategies, by Company, 2021-2023*
Figure 28. Product Mapping of Top 10 Players
Figure 29. Competitive Dashboard
Figure 30. Competitive Heatmap: Intravenous (IV) Hydration Therapy Market
Figure 31. Top Player Positioning, 2023
Figure 32. Davita: Net Sales, 2021-2023 ($Billion)
Figure 33. Davita: Revenue Share, by Segment, 2023 (%)
Figure 34. Davita: Revenue Share, by Region, 2023 (%)
Figure 35. Nikkiso Co. Ltd.: Net Sales, 2021-2023 ($Billion)
Figure 36. Nikkiso Co. Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 37. Nikkiso Co. Ltd.: Revenue Share, by Region, 2023 (%)
Figure 38. Core IV Therapy, LLC: Net Sales, 2021-2023 ($Billion)
Figure 39. Core IV Therapy, LLC: Revenue Share, by Segment, 2023 (%)
Figure 40. Core IV Therapy, LLC: Revenue Share, by Region, 2023 (%)
Figure 41. Cryojuvenate UK Ltd.: Net Sales, 2021-2023 ($Billion)
Figure 42. Cryojuvenate UK Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 43. Cryojuvenate UK Ltd.: Revenue Share, by Region, 2023 (%)
Figure 44. B. Braun Medical Inc.: Net Sales, 2021-2023 ($Billion)
Figure 45. B. Braun Medical Inc.: Revenue Share, by Segment, 2023 (%)
Figure 46. B. Braun Medical Inc.: Revenue Share, by Region, 2023 (%)
Figure 47. Otsuka Pharmaceutical Co. Ltd.: Net Sales, 2021-2023 ($Billion)
Figure 48. Otsuka Pharmaceutical Co. Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 49. Otsuka Pharmaceutical Co. Ltd.: Revenue Share, by Region, 2023 (%)
Figure 50. Nexgen Health: Net Sales, 2021-2023 ($Billion)
Figure 51. Nexgen Health: Revenue Share, by Segment, 2023 (%)
Figure 52. Nexgen Health: Revenue Share, by Region, 2023 (%)
Figure 53. Jw Life Science Corporation: Net Sales, 2021-2023 ($Billion)
Figure 54. Jw Life Science Corporation: Revenue Share, by Segment, 2023 (%)
Figure 55. Jw Life Science Corporation: Revenue Share, by Region, 2023 (%)
Figure 56. Amanta Healthcare Limited.: Net Sales, 2021-2023 ($Billion)
Figure 57. Amanta Healthcare Limited.: Revenue Share, by Segment, 2023 (%)
Figure 58. Amanta Healthcare Limited.: Revenue Share, by Region, 2023 (%)
Figure 59. Baxter International Inc.?: Net Sales, 2021-2023 ($Billion)
Figure 60. Baxter International Inc.?: Revenue Share, by Segment, 2023 (%)
Figure 61. Baxter International Inc.?: Revenue Share, by Region, 2023 (%)

Companies Mentioned

Key Market Players in the Intravenous Market include:
  • Davita
  • Nikkiso Co. Ltd.
  • Core IV Therapy, LLC
  • Cryojuvenate UK Ltd.
  • B. Braun Medical Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • NexGen Health
  • JW Life Science Corporation
  • Amanta Healthcare Limited.
  • Baxter International Inc.?

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information